Employing a peptide-based nanoscale drug delivery system is an effective strategy to overcome the poor therapeutic outcomes of chemotherapeutic drugs. Here, we developed a self-assembling peptide-drug delivery system comprising a self-assembling anticancer peptide (R-lycosin-I), as revealed in our previous study, and 10-hydroxycamptothecin (HCPT) for cancer therapy. The results showed that peptide-drug conjugates (R-L-HCPT) could assemble into nanospheres of 40–60 nm in water. Compared with free HCPT, R-L-HCPT nanospheres not only inhibited tumor growth but also suppressed pulmonary metastatic nodules on B16–F10 cells in vivo. In summary, these results indicated that the self-assembling R-lycosin-I could provide a promising nanoscale platform for delivering small-molecule drugs. Moreover, our study might provide new opportunities for the development of a new class of functional peptide-drug-conjugated systems based on nanomaterials, which could synergistically enhance anticancer outcomes.

中文翻译：

---

基于药物的肽基纳米球抑制癌症的转移和生长。

采用基于肽的纳米级药物递送系统是克服化学治疗药物不良治疗结果的有效策略。在这里，我们开发了一种自组装肽-药物递送系统，该系统包括自组装抗癌肽（R-lycosin-I）（如我们先前的研究所述）和10-羟基喜树碱（HCPT）用于癌症治疗。结果表明，肽-药物偶联物（RL-HCPT）可以在水中组装成40–60 nm的纳米球。与游离HCPT相比，RL-HCPT纳米球不仅可以抑制肿瘤的生长，而且还可以体内抑制B16–F10细胞上的肺转移性结节。总而言之，这些结果表明自组装的R-lycosin-I可以提供一个有希望的纳米级平台，用于递送小分子药物。此外，我们的研究可能为开发新型的基于纳米材料的功能性肽-药物偶联系统提供新的机会，这可以协同增强抗癌效果。